Sophie Tanguay is a graduate of Laval University where she obtained a Master of Science in Neurobiology and a Bachelor’s degree in Molecular Biology. Sophie is an accomplished pharmaceutical industry executive with more than 20 years of extensive experience in roles such as Strategic Drug Development, Global Strategic Leadership, Clinical Development and Regulatory Affairs. Prior to joining the MHICC, she led an Innovative Product Development and Portfolio Strategy Team, where she played an instrumental role in the evaluation of technologies, pipelines and products for mergers and acquisitions (M&A), joint ventures (JV) and in-licensing opportunities with a goal to expand the company’s portfolio. In addition, she brings a wealth of knowledge as a consultant for academic institutions, pharmaceutical and healthcare companies, and biotechnology organizations with her in-depth understanding of new and old drugs, medical devices, natural health products/dietary supplements, consumer goods and cosmetics. Sophie was a key player in the successful development of many products in the fields of neurology, gastroenterology, oncology and cardiology.